https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42673 Wed 31 Aug 2022 16:25:24 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51294 Wed 30 Aug 2023 13:37:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41487 Wed 24 Aug 2022 15:37:00 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51394 Wed 24 Apr 2024 12:04:11 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55186 Wed 24 Apr 2024 09:56:15 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40887 Wed 20 Jul 2022 10:39:49 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40374 Wed 13 Mar 2024 08:55:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52192 Wed 13 Mar 2024 08:03:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14697 Wed 11 Apr 2018 14:52:04 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29497 Wed 11 Apr 2018 12:30:49 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15269 Wed 11 Apr 2018 10:59:20 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47819 11.0 µmol/L (p = 0.012), cysteine levels were <255 µmol/L (p = 0.033) and serum folate was <22.0 nmol/L (p = 0.003; in males only). In females, dietary intake of total folate <336 µg/day (p=0.001), natural folate <270 µg/day (p = 0.011), and vitamin B2 < 1.12 mg/day (p = 0.028) was associated with an increased AD risk. These results support Hcy, Cys, and SF as useful biomarkers for AD, irrespective of APOE4 genotype and as such should be considered as part of screening and managing risk of AD.]]> Wed 01 Feb 2023 09:58:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43642 Tue 27 Sep 2022 09:38:50 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48285 Tue 14 Mar 2023 10:57:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41379 Tue 04 Apr 2023 19:08:51 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:412 = 6.6 v <= 5.0 mmol/L 1.27 (1.06-1.53); and not ever having had a raised cholesterol 1.20 (1.04-1.40). There was no difference in cardiovascular disease end points and death in those who were and were not initiated on drug therapy at randomization. Conclusions: Failure to initiate antihypertensive therapy for patients at the randomization visit was associated with lower BP measurements, previous drug therapy, younger age, and a historic or current raised cholesterol, but not with overt cardiovascular disease or other risk factors. There was no difference in cardiovascular disease end points and death in those who were and were not initiated on drug therapy at randomization.]]> Thu 25 Jul 2013 09:09:51 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49992 Thu 22 Jun 2023 14:05:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54292 Thu 15 Feb 2024 14:45:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52479 Thu 12 Oct 2023 14:20:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50801 Sun 06 Aug 2023 09:12:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41252 Sat 30 Jul 2022 12:54:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7234 Sat 24 Mar 2018 08:33:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12862 Sat 24 Mar 2018 08:14:48 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10534 Sat 24 Mar 2018 08:13:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10291 Sat 24 Mar 2018 08:13:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10083 Sat 24 Mar 2018 08:12:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21173 P = 0.004) and role limitations due to emotional factors (OR 1.6, 95% CI 1.0–2.5; P = 0.002) were associated with starting participation. Decline in mental health-related quality of life (OR 4.1, 95% CI 2.3–7.2; P < 0.0001) was associated with stopping. Conclusion: Changed participation was associated with change in functional capacity and tied to emotional well-being.]]> Sat 24 Mar 2018 07:58:04 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30191 Sat 24 Mar 2018 07:41:32 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27698 Sat 24 Mar 2018 07:40:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28454 Sat 24 Mar 2018 07:39:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25814 Sat 24 Mar 2018 07:34:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25689 Sat 24 Mar 2018 07:28:23 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27754 Sat 24 Mar 2018 07:27:43 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25876 Sat 24 Mar 2018 07:25:54 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26746 70 years) living at home who initially reported taking greater than five medications. Medication review by an experienced hospital pharmacist within the ED. Rate of admission, rate of readmission, length of stay and admission to an aged care facility at 4 months post presentation, and rate of general practitioner acceptance of pharmacist recommendations. Results: The odds of admission decreased for those receiving the intervention (odds ratio [OR] = 0.68, 95% confidence interval [CI]: 0.53, 0.87; P = 0.002). There was no evidence that the intervention affected hospital length of stay for admitted patients (0.09 days change, 95% CI -0.08, 0.25; P = 0.31), the rate of re-presentation (0.08% change, 95% CI -0.12, 0.28; P = 0.44) or admission to an aged care facility. The odds of admission to an aged care facility increased with the Identification of Seniors at Risk score. General practitioners adopted 49% of pharmacists' recommendations. Conclusions: The presence of an experienced pharmacist in the ED reduced hospital admissions. Further study is required to determine longer term impacts of General Medical Practitioner acceptance of pharmacists' recommendations.]]> Sat 24 Mar 2018 07:24:48 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22535 Sat 24 Mar 2018 07:15:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53415 Mon 27 Nov 2023 11:19:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54966 Mon 25 Mar 2024 12:11:04 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44764 Mon 24 Oct 2022 08:49:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47596 Mon 23 Jan 2023 14:56:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52506 Mon 16 Oct 2023 10:23:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44215 85% for most of the latent statuses. All factors but diabetes mellitus among the CHA2DS2-VA scoring scheme were independently associated with latent status membership at the time of AF diagnosis. Conclusions: Evaluation of pharmacological treatment indicates that prevention of thromboembolism is inadequate among women with AF. There exists wide variations in medication patterns. However, once in a particular pattern, women are likely to continue the same medications long-term. This underscores the importance of initial assessment of patient profile and stroke risk score in determining the treatment for AF. Failure to assess risk makes women susceptible to devastating AF complications.]]> Mon 10 Oct 2022 16:52:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53098 Fri 17 Nov 2023 11:27:06 AEDT ]]>